Tuesday, October 30, 2018

Halozyme Inks $25M Licensing Deal With Roche

San Diego-based biotechnology developer Halozyme Therapeutics announced this morning that it has licensed some of its drug delivery technology to Roche, in a deal worth $25M upfront, and a potential to earn another $160M to $165M per target. According to Halozyme, the licensing deal covers its ENHANZE drug delivery technology, for use in a new undisclosed clinical stage therapeutic target, with an option to select two additional targets within four years.